Geron Corp (GERN)

[tradetrak]

Yes, that's where that Seeking Alpha info must have come from and it does indeed mention the 20 patients discontinuing participation. But it also mentions that the company believes that, "the total accrued patients in the Myelofibrosis IST will be adequate for gathering additional and updated safety and efficacy data to support the imetelstat development program."
Bottom line, there's the usual forward-looking disclaimer but I don't see any negative surprises in this filing.

http://www.sec.gov/Archives/edgar/data/886744/000120677414000309/0001206774-14-000309.txt

From the 8-K:
Mayo Clinic has informed Geron Corporation that effective January 22, 2014, the Myelofibrosis IST has been closed to new patient enrollment, and that the remaining patients in the study will continue to receive imetelstat treatment and be followed under the Myelofibrosis IST protocol. The Company believes that approximately 79 patients have been enrolled in the Myelofibrosis IST, including nine patients with blast-phase myelofibrosis and nine patients with refractory anemia with ringed sideroblasts; a subpopulation of myelodysplastic syndromes, and that approximately 20 patients have discontinued from the study since its inception.

In December 2013 at the American Society of Hematology Annual Meeting, the investigator presented preliminary data from the first two cohorts of patients in the Myelofibrosis IST, including preliminary efficacy data for 22 patients and preliminary safety data for 33 patients. Based on this preliminary efficacy and safety data, the Company plans to initiate a Geron-sponsored, multi-center, Phase 2 clinical trial of imetelstat in patients with myelofibrosis in the first half of 2014. The Company also believes that the total accrued patients in the Myelofibrosis IST will be adequate for gathering additional and updated safety and efficacy data to support the imetelstat development program.